Now I have sufficient information to write the consolidated review. Let me synthesize everything.

## Summary

The paper introduces HG-DCM, a framework that combines a neural network with a compartmental model (DELPHI) for early-stage pandemic forecasting. The core innovation is cross-disease temporal transfer: the NN learns to predict DELPHI parameters by training on data from historical pandemics (Ebola, SARS, Dengue, seasonal influenza) alongside the limited early data from a current outbreak (COVID-19). The method is well-motivated, cleanly architected, and the ablation study provides some evidence that historical guidance helps.

## Strengths

1. **Novel cross-disease temporal transfer paradigm.** The paper is the first to systematically leverage data from multiple biologically distinct pandemics to forecast a newly emerging one via a neural-network-predicted compartmental model. This directly addresses the cold-start problem where standard single-disease models fail due to data scarcity. The motivation is grounded in an epidemiological observation—that human-driven macroscopic dynamics generalize across diseases—and the operationalization through a shared parameter-prediction network is clean.

2. **Methodologically sound and interpretable architecture.** The two-stage pipeline (ResNet → fully connected layers → DELPHI ODE solver) is clearly described. The removal of Batch Normalization due to cross-pandemic batch-statistic mismatch is a principled design choice tailored to the setting. The use of a sigmoid ranging function to keep predicted parameters within physical bounds preserves epidemiological interpretability while enabling end-to-end learning.

3. **Meaningful ablation isolating the contribution of historical data.** The comparison between HG-DCM and T-DCM (which removes historical data and metadata) shows that historical guidance consistently improves median MAE across all training horizons. This isolates the core claim. The overshooting analysis (Figure 4a) is also informative: HG-DCM dramatically reduces overshooting events compared to DELPHI.

4. **Construction of a multi-pandemic dataset.** The authors compiled a dataset spanning COVID-19, Ebola, SARS, Dengue, and seasonal influenza with metadata—a resource that enables the cross-disease learning and is a contribution in its own right.

## Weaknesses

### Major

1. **SOTA comparison is limited to two locations, while the abstract claims broad outperformance.** Table 1 compares HG-DCM against GradABM and EiNNs only for the United States and Massachusetts, with the paper transparently noting that data/code for these baselines was unavailable for other locations. However, the abstract states that HG-DCM "consistently and significantly outperforms state-of-the-art methods … across 258 global locations." The DELPHI comparison (Table 2) does span 258 locations, but the "advanced deep learning-only models" comparison does not. This mismatch between the evidence presented and the strength of the claim in the abstract is a significant overstatement.

2. **Mixed ablation results are not adequately explained.** Table 2 shows that HG-DCM's *mean* MAE is *higher* than the CNN baseline at 2 weeks (18,603 vs 15,600) and dramatically higher at 4 weeks (110,452 vs 11,238—a ~10× gap). The paper focuses on median MAE (where HG-DCM leads at 2 and 4 weeks) but does not analyze the extreme outliers that inflate the mean, or explain why these failures occur predominantly at 4 weeks. Similarly, HG-DCM wins on median MAE at 2 and 4 weeks but loses at 6 and 8 weeks to CNN and DELPHI respectively. The narrative that HG-DCM "consistently outperforms" is not uniformly supported by the data.

3. **No evaluation on any non-COVID pandemic.** The method is presented as a general cross-disease transfer framework, yet it is tested only on COVID-19 forecasting. A leave-one-pandemic-out evaluation (e.g., train on all diseases except SARS and evaluate on SARS) would directly test the generalizability claim. Without this, the evidence that the transfer works beyond COVID-19 remains circumstantial.

### Minor

4. **Parameter "realism" claims are not validated against ground truth.** The paper argues that HG-DCM's lower-variance parameters are "more conservative and realistic" (Section 3.2.3). However, the ground truth values of latent epidemiological parameters (infection rate, median day of action) are unknown. Lower variance could partly reflect bias induced by historical data rather than genuine improvement. The better forecasting performance provides indirect support, but the direct claim about parameter realism is not supported.

5. **Loss weighting hyperparameters (α and β) are not analyzed.** The objective function (Eqns. 3–5) introduces α to balance MAE/MAPE within a location and β to balance historical vs. current pandemic loss. Neither the chosen values nor a sensitivity analysis are reported in the main text. Since the balance between historical and current loss is central to the method, the robustness of results to β is important to establish.

6. **No uncertainty quantification.** The paper evaluates only point forecasts (MAE of cumulative cases). For a public-health-facing tool, prediction intervals are highly desirable. The authors note this is future work, which is acceptable, but it limits the practical impact demonstrated.

7. **Single MAE metric without location normalization.** MAE of cumulative cases is not normalized by population, so a few large-population regions can dominate the unweighted average. Reporting mean and median separately helps but does not fully address this.

### Trivial

- The paper mentions removing Batch Normalization as a design choice but does not ablate it (the critic's suggestion of an easy experiment is reasonable, but the absence is not a flaw in the presented claims).
- The main text references the appendix for architecture details and baseline setup, which is standard for the venue format.

## Nice-to-Haves

- A leave-one-pandemic-out evaluation to directly test cross-disease generalization.
- A sensitivity analysis for the loss weighting hyperparameter β.
- Analysis of the failure cases that produce the extreme outliers at 4-week training horizon.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **"Missing appendix content" (harsh critic):** The critic notes that "the neural network architecture specifics … are not given in the main text" and that the appendix presumably contains them. Since the parser strips all appendices, penalizing missing appendix content violates the hard rules. Removed.
- **"No held-out validation split described" (harsh critic):** This may be in the stripped appendix. Even if not, it is a minor detail that does not rise to the level of a weakness given the page constraints. Removed (trivial if present, but likely addressed in appendix).
- **"No computational cost or training time is reported" (harsh critic):** This is a minor omission that does not affect the validity of the core claim. Removed per the filter on trivial reproducibility nitpicks.
- **"No testing on any pandemic other than COVID-19" is already covered under Major weakness #3.** The critic also suggests a held-out historical pandemic test, which is the same point. Merged.
- **Strength Finder: "First systematic cross-disease temporal transfer framework"** and **"Construction of a comprehensive multi-pandemic dataset"** are concrete and specific. Kept.
- **Strength Finder: "Consistent empirical improvement … 6 out of 8 tasks"** — this is accurate for Table 1 but the critic correctly notes the limited scope. The strength is factually correct but the qualification (2 locations) is important. Reworded to avoid overclaiming.

## Novel Insights

The primary insight that emerges from this review is that the paper's core methodological contribution—training a neural network to predict compartmental-model parameters using data from multiple historical pandemics—is genuinely novel and well-executed, but the experimental evaluation sits below the standard required to fully substantiate the strong claims made in the abstract. The most striking gap is the disconnect between the broad outperformance claims ("across 258 global locations") and the fact that the two hardest baselines (GradABM, EiNNs) are only compared on two locations. The ablation results, while partially supportive, also reveal unexpected failure modes (the 4-week mean MAE spike) that the paper does not engage with.

## Suggestions

1. **Tone down the abstract and introduction claims** to match what is actually demonstrated: outperformance over DELPHI across 258 locations, and over GradABM/EiNNs on the 2 locations where those models could be run.
2. **Add a leave-one-pandemic-out evaluation** to directly test cross-disease generalization.
3. **Analyze the failure cases** driving the mean MAE inflation at 4-week training horizon, and discuss what types of locations/settings cause HG-DCM to produce extreme errors.
4. **Add a sensitivity analysis** for the loss weighting parameter β, showing that results are not highly sensitive to its value.
5. **Include standard errors or confidence intervals** for the Table 2 MAE results across locations.

## Score and Decision

**Calibration Anchors (all rounds):**

| Anchor | Avg Score | Round | Comparison to this paper |
|--------|-----------|-------|-------------------------|
| V83xzYnZ5q (TB prediction) | 3.00 | R1 (low) | Lower novelty/evaluation; weak reject |
| CpiOUOaqh3 (SEIR parameter opt) | 2.00 | R1 (low) | Significantly weaker methodology |
| DL7JWbdGr3 (PEMs - pre-trained epidemic models) | 4.75 | R1 (mid), R2 (mid) | **Most directly comparable.** PEMs also does cross-disease learning for epidemic forecasting. PEMs has broader evaluation (multiple diseases/tasks) but less novel methodology. This paper has more novel methodology but narrower evaluation. Slightly stronger than PEMs overall. |
| NvDRvtrGLo (TRENDy) | 5.00 | R1 (mid), R2 (mid) | Different topic (PDE learning), comparable quality level |
| Gc2qkiYUkh (transfer learning theory) | 5.20 | R2 (mid) | Theory paper, not directly comparable |
| qq0zZMC4SM (synthetic datasets for spatiotemporal graphs) | 5.00 | R2 (mid) | Different topic, comparable quality |
| 2U8owdruSQ (DNN evaluation for stochastic processes) | 6.80 | R2 (mid) | Higher: more rigorous evaluation and clearer contribution |
| bWcnvZ3qMb (FITS - time series) | 8.00 | R1 (high) | Significantly stronger: clean, well-evaluated, impactful |

**Round-1 bracket:** 4–6. **Round-2 narrowing:** The most directly comparable anchor (PEMs, 4.75, rejected) shares similar evaluation gaps (limited baselines, hard to isolate contribution) but HG-DCM has superior methodological novelty. After reading PEMs fully and comparing, this paper is slightly stronger in conception but equally limited in evaluation breadth. **Final score: 5.0.** This reflects a paper with a genuinely novel core idea and clean methodology, but whose experimental evaluation does not fully match the strength of the claims made. It sits in the weak reject / borderline zone—the contribution is real but the evidence is not yet commensurate with the narrative.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>